NO20073510L - Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer - Google Patents

Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer

Info

Publication number
NO20073510L
NO20073510L NO20073510A NO20073510A NO20073510L NO 20073510 L NO20073510 L NO 20073510L NO 20073510 A NO20073510 A NO 20073510A NO 20073510 A NO20073510 A NO 20073510A NO 20073510 L NO20073510 L NO 20073510L
Authority
NO
Norway
Prior art keywords
methods
retinol
treatment
related diseases
compositions
Prior art date
Application number
NO20073510A
Other languages
English (en)
Norwegian (no)
Inventor
Kenneth J Widder
Jay Lichter
Original Assignee
Sirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirion Therapeutics Inc filed Critical Sirion Therapeutics Inc
Publication of NO20073510L publication Critical patent/NO20073510L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20073510A 2004-12-08 2007-07-06 Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer NO20073510L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63444904P 2004-12-08 2004-12-08
US66092405P 2005-03-10 2005-03-10
US66090405P 2005-03-11 2005-03-11
US67240505P 2005-04-18 2005-04-18
US69851205P 2005-07-11 2005-07-11
PCT/US2005/044416 WO2006063128A2 (en) 2004-12-08 2005-12-07 Methods, assays and compositions for treating retinol-related diseases

Publications (1)

Publication Number Publication Date
NO20073510L true NO20073510L (no) 2007-09-06

Family

ID=35735778

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20073510A NO20073510L (no) 2004-12-08 2007-07-06 Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer
NO20075018A NO20075018L (no) 2004-12-08 2007-10-04 Fremgangsmater, analyser og preparater for behandling av diabetes type I eller II

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20075018A NO20075018L (no) 2004-12-08 2007-10-04 Fremgangsmater, analyser og preparater for behandling av diabetes type I eller II

Country Status (18)

Country Link
US (3) US20060135460A1 (pt)
EP (3) EP1930046A1 (pt)
JP (3) JP4178281B2 (pt)
KR (2) KR100971695B1 (pt)
CN (3) CN101072555B (pt)
AU (3) AU2005314039B2 (pt)
BR (2) BRPI0520207A2 (pt)
CA (2) CA2584845C (pt)
EA (2) EA010827B1 (pt)
GB (1) GB2421433B (pt)
GE (1) GEP20094644B (pt)
IL (2) IL182837A0 (pt)
LV (1) LV13666B (pt)
MX (1) MX2007006245A (pt)
NO (2) NO20073510L (pt)
NZ (2) NZ561148A (pt)
SG (1) SG144145A1 (pt)
WO (1) WO2006063128A2 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
EP1722766A2 (en) * 2004-02-17 2006-11-22 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
KR20070091283A (ko) * 2004-11-04 2007-09-10 시리온 테라퓨틱스, 인크. 레티놀-레티놀 결합단백질(ｒｂｐ)-트랜스타이레틴(ｔｔｒ) 복합체 형성의조절 인자
BRPI0520207A2 (pt) * 2004-12-08 2012-09-25 Revision Therapeutics Inc uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
CA2626441A1 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
WO2008131368A2 (en) 2007-04-20 2008-10-30 Acucela Inc. Styrenyl derivative compounds for treating ophthalmic diseases and disorders
CN103664637B (zh) 2007-06-29 2016-02-03 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
EP2687208A1 (en) * 2007-09-12 2014-01-22 The Trustees of Columbia University in the City of New York Compositions and Methods for Treating Macular Degeneration
CA2704199C (en) * 2007-11-01 2016-01-19 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
CN101452001B (zh) * 2007-12-06 2013-07-24 王颖 化学发光磁酶免疫法定量检测rbp4试剂盒
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
WO2009138437A1 (en) * 2008-05-13 2009-11-19 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
CN101307314B (zh) * 2008-07-04 2011-12-14 中国医学科学院医学生物学研究所 重组噬菌体rbp/t7的构建及用其制备2型糖尿病疫苗的方法
WO2010040446A1 (en) 2008-10-09 2010-04-15 Merck Patent Gmbh Estrogen and anti-estrogen marker genes
SG10201809460SA (en) 2008-10-20 2018-11-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of transthyretin
US8431356B2 (en) 2009-01-22 2013-04-30 Regents Of The University Of Minnesota Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium atpase and phospholamban
US20100239552A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders
US8575217B2 (en) * 2009-03-16 2013-11-05 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
ES2549916T3 (es) * 2009-05-04 2015-11-03 Acucela, Inc. Composiciones para usar en el tratamiento de glaucoma o hipertensión ocular
WO2011056883A1 (en) 2009-11-03 2011-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
AU2015264811A1 (en) * 2010-03-29 2016-01-07 Alnylam Pharmaceuticals, Inc. SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
US20130281510A1 (en) * 2010-03-29 2013-10-24 Kumamoto University siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
SG194843A1 (en) * 2011-05-18 2013-12-30 Univ California Compositions and methods for treating retinal diseases
WO2013075035A1 (en) 2011-11-18 2013-05-23 Alnylam Pharmaceuticals Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2013166041A1 (en) * 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
EP2953970A4 (en) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
CN104774840B (zh) * 2014-01-10 2019-09-17 中国人民解放军第三军医大学第一附属医院 基因突变体及其应用
BR112016025356B1 (pt) 2014-04-30 2023-04-18 The Trustees Of Columbia University In The City Of New York Compostos de 4-fenilpiperidinas substituídas, composições e seus usos
LT3185957T (lt) 2014-08-29 2022-09-26 Alnylam Pharmaceuticals, Inc. Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
WO2016160718A1 (en) 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
PL3329002T3 (pl) 2015-07-31 2021-04-19 Alnylam Pharmaceuticals, Inc. Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
US20190134069A1 (en) * 2016-04-22 2019-05-09 Viking Therapeutics, Inc. Use of thyroid beta-agonists
KR102407059B1 (ko) 2016-04-22 2022-06-10 바이킹 테라퓨틱스 인코포레이티드 갑상선 베타-작용제의 사용
MY194096A (en) 2016-04-28 2022-11-11 Spark Therapeutics Inc Relative potency assay for viral vector encoding isomerhydrolases
GB201706009D0 (en) * 2017-04-13 2017-05-31 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of stargardt disease
BR112020005230A2 (pt) 2017-09-19 2020-09-24 Alnylam Pharmaceuticals, Inc. composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
EP3709990A4 (en) * 2017-11-17 2021-12-01 The Regents of the University of California MANIPULATION OF THE RETINOIC ACID SIGNALING ROUTE
US20220184102A1 (en) * 2019-03-27 2022-06-16 University Of Virginia Patent Foundation Compositions and methods for treating age-related macular degeneration
KR102266963B1 (ko) * 2019-12-12 2021-06-18 연세대학교 산학협력단 렙틴 및 카로티노이드 관련 대사체, 및 피하지방면적을 이용한 식이 제한 후 비만의 대사적 상태를 예측하는 방법
CN112043820B (zh) * 2020-09-16 2022-06-21 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CA3227852A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
CN116570724A (zh) * 2023-05-17 2023-08-11 四川大学 一种基于肿瘤微环境激活型高尔基体靶向干扰剂的纳米粒

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US529455A (en) 1893-10-14 1894-11-20 Detachably securing gun-barrels to stocks
USRE29169E (en) 1971-02-10 1977-04-05 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4474878A (en) 1975-09-29 1984-10-02 Cordis Laboratories, Inc. Sandwich EIA for antigen associated with hepatitis
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4310546A (en) 1978-07-31 1982-01-12 Johnson & Johnson Novel retinoids and their use in preventing carcinogenesis
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4618485A (en) 1982-03-12 1986-10-21 International Immunoassay Laboratories, Inc. Kinetic radioimmunoassay test method and device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4743400A (en) 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5814612A (en) * 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6506917B1 (en) * 1991-12-18 2003-01-14 The Salk Institute For Biological Studies Compounds and compositions useful for modulation of processes mediated by RXR
US5591646A (en) 1992-09-02 1997-01-07 Arris Pharmaceutical Method and apparatus for peptide synthesis and screening
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
EP0671953A4 (en) 1992-11-13 1996-01-10 Univ Ohio State Res Found C-GLYCOSIDE ANALOG OF N- (HYDROXYPHENYL) RETINAMIDE-O-GLUCURONID.
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
DE69533921T2 (de) 1994-03-23 2005-12-01 Alexion Pharmaceuticals, Inc., New Haven Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
US5427571A (en) * 1994-08-08 1995-06-27 Cor-A-Vent Incorporated Ventilated cap system for the ridge of a roof
JPH08136546A (ja) 1994-11-15 1996-05-31 Bio Sensor Kenkyusho:Kk 物質分析法
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5866341A (en) 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
AU5727798A (en) * 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US5955305A (en) * 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
CZ300929B6 (cs) * 1997-08-15 2009-09-16 Duke University Sloucenina pro použití pri lécení nebo prevenci estrogenem stimulované rakoviny
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
ATE323871T1 (de) * 1998-12-17 2006-05-15 Diversi Plast Products Inc Firstkappenlüftung
US6343257B1 (en) 1999-04-23 2002-01-29 Peptor Ltd. Identifying pharmacophore containing combinations of scaffold molecules and substituents from a virtual library
US6128870A (en) * 1999-05-24 2000-10-10 Kohler; Raymond L. Roof vent system
EP1216221A2 (en) * 1999-09-14 2002-06-26 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
WO2001038344A2 (en) * 1999-11-23 2001-05-31 Gerhart Graupner Modulation of signal transduction
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
US6450882B1 (en) * 2000-08-30 2002-09-17 Liberty Diversified Industries, Inc. Precipitation resistant ridge vent
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
JP2004526807A (ja) * 2001-05-29 2004-09-02 ケビジェン カンパニー リミテッド 新規のレチノイド誘導体及びその製造方法並びにその化合物を含有する抗癌剤組成物
DE60208792T2 (de) * 2001-06-22 2006-08-31 Merck & Co., Inc. Tyrosin-kinase inhibitoren
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US20040014131A1 (en) * 2002-07-09 2004-01-22 Pfizer Inc. Assay methods
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
JP2006514094A (ja) * 2002-11-29 2006-04-27 ゲーペーツェー バイオテック アクチェンゲゼルシャフト Ｃ型肝炎ウイルス感染に対して有用な製剤
FI20030426L (fi) * 2003-03-24 2004-09-25 Tomi Jaervinen Syklodekstriinikompleksit
JP4869942B2 (ja) * 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
NZ550340A (en) * 2004-03-17 2010-08-27 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle using a retinoid
KR20140140616A (ko) * 2004-06-18 2014-12-09 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 시각 이상 치료를 위한 레티날 유도체 및 이를 이용하기 위한 방법
PL1768657T3 (pl) * 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US20080033053A1 (en) * 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
WO2006033734A2 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
KR20070091283A (ko) * 2004-11-04 2007-09-10 시리온 테라퓨틱스, 인크. 레티놀-레티놀 결합단백질(ｒｂｐ)-트랜스타이레틴(ｔｔｒ) 복합체 형성의조절 인자
BRPI0520207A2 (pt) * 2004-12-08 2012-09-25 Revision Therapeutics Inc uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding

Also Published As

Publication number Publication date
EP1930046A1 (en) 2008-06-11
NO20075018L (no) 2007-09-06
GB2421433B (en) 2008-01-02
GB0525041D0 (en) 2006-01-18
EA011154B1 (ru) 2009-02-27
EA200701218A1 (ru) 2007-10-26
JP4178281B2 (ja) 2008-11-12
BRPI0518616A (pt) 2008-01-15
CN101129344A (zh) 2008-02-27
EA010827B1 (ru) 2008-12-30
SG144145A1 (en) 2008-07-29
EP2289500A1 (en) 2011-03-02
EP1827407A2 (en) 2007-09-05
US20120202885A1 (en) 2012-08-09
CN101072555B (zh) 2011-06-29
KR20070086074A (ko) 2007-08-27
CN102240278A (zh) 2011-11-16
AU2010200842A1 (en) 2010-04-01
EP1827407A4 (en) 2008-05-21
CA2584845A1 (en) 2006-06-15
AU2007229394B9 (en) 2010-02-18
AU2007229394A1 (en) 2007-11-08
CA2584845C (en) 2009-02-17
CA2638753A1 (en) 2006-06-15
EA200701828A1 (ru) 2008-02-28
KR100890410B1 (ko) 2009-03-26
AU2005314039A1 (en) 2006-06-15
WO2006063128A3 (en) 2006-08-17
US20060135460A1 (en) 2006-06-22
KR100971695B1 (ko) 2010-07-23
MX2007006245A (es) 2007-07-25
GEP20094644B (en) 2009-03-10
IL182837A0 (en) 2008-04-13
AU2007229394B2 (en) 2009-12-10
IL185761A0 (en) 2008-01-20
US20120309835A1 (en) 2012-12-06
KR20070102591A (ko) 2007-10-18
WO2006063128A2 (en) 2006-06-15
CN101072555A (zh) 2007-11-14
JP2012097083A (ja) 2012-05-24
BRPI0520207A2 (pt) 2012-09-25
GB2421433A (en) 2006-06-28
LV13666B (en) 2008-07-20
NZ561148A (en) 2008-12-24
NZ554734A (en) 2009-03-31
JP2008523080A (ja) 2008-07-03
AU2005314039B2 (en) 2008-01-31
JP2008179648A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
NO20073510L (no) Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer
NO20080718L (no) Preparat for behandling av oftalmiske lidelser via serumretinol, serumretinol-bindingsprotein (RBP) og/eller serumretinol-RBP-modulering
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
NO20054292L (no) Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende dette
WO2007056021A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007053189A3 (en) Compositions and methods for altering immune function
WO2007056220A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
WO2006052860A3 (en) Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
WO2007046083A3 (en) Compositions for treatment of eye diseases
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
BR112018070459A2 (pt) inibidor da c1 esterase conjugado e usos do mesmo
WO2022026592A3 (en) Antibody molecules to coronavirus and uses thereof
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2021074786A3 (en) Non-hemolytic compositions and methods of use for recovering disease causing toxic constituents in the blood
MX2011005845A (es) Metodos, analisis y composiciones para tratar enfermedades relacionadas con retinol.
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
HRP20050580B1 (hr) Sinergistiäśki uäśinak kombinacije roflumilasta i (r,r)-formoterola
WO2006031930A3 (en) Modulation of xbp-1 activity for treatment of metabolic disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application